Summary
Synopsis: Doxepin1 is closely related in structure and general pharmacological properties to other tricyclic antidepressant drugs such as amitriptyline and imipramine. It combines antidepressant activity with a sedative effect and in this respect resembles amitriptyline, with which it shares a similar profile of clinical action.
The mood elevating effect of doxepin appears to be similar to that of amitriptyline but is probably less marked than that of imipramine and in some studies has been slower to take effect than imipramine. At dosages which have achieved a similar overall response rate, doxepin tends to cause fewer or less troublesome side-effects than imipramine, amitriptyline or amitriptyline-perphenazine. The more marked sedative properties of doxepin make it more useful than imipramine in depressed patients with sleep disturbances and in depression associated with anxiety. The benzodiazepines remain the drugs of choice in anxiety states, but when anxiety is accompanied by significant depression, doxepin is more effective than chlordiazepoxide or diazepam.
Doxepin is usually well tolerated, and in particular by the elderly and those with cardiovascular disease. Side-effects are similar in nature to those of other tricyclic antidepressants, with dry mouth, drowsiness and constipation being the most common. Postural hypotension is uncommon. Although doxepin appears to cause fewer cardiovascular side-effects in usual therapeutic doses, it has an intrinsic cardiotoxicity on overdosage similar to other tricyclics.
Pharmacodynamic studies: In rodents, doxepin has been shown to antagonize the central depressant effects of reserpine and tetrabenazine, to suppress spontaneous motility and conditioned avoidance behaviour, and to potentiate and prolong the stimulant actions of amphetamine and levodopa, to an extent similar to that observed with amitriptyline. Doxepin also possesses tranquillizing properties similar to the benzodiazepines, but it lacks muscle relaxant properties. Its central and peripheral anticholinergic properties are less than those of amitriptyline, and the cardiovascular effects are similar to other tricyclics — lowered blood pressure, increased heart rate, reduced total peripheral resistance and, at higher doses, cardiac arrhythmias. Compared with other tricyclic antidepressants, doxepin is only a weak inhibitor of norepinephrine or serotonin uptake into peripheral organs or the brain, although it potentiates pressor responses to norepinephrine and blocks those to tyramine.
In man, doxepin produces EEG changes typical of the tricyclic antidepressants. Its cardiovascular effects are minimal, even in patients with myocardial disease, and hypotension has occurred in only a small proportion of patients during therapy. Doxepin, unlike other tricyclic antidepressants, appears to have little effect on intracardiac conduction, but like other tricyclic antidepressants, it disturbed cardiac rhythm on overdosage. Doxepin potentiates pressor responses to epinephrine, blocks those to tyramine, and at doses above 200mg daily reverses the antihypertensive effects of adrenergic neuron blocking agents like guanethidine and bethanidine. A major metabolite of doxepin, desmethyldoxepin, is pharmacologically active. Thus in the body, pharmacological effects are exerted by a mixture of doxepin and its active metabolite(s).
Pharmacokinetic studies: Results of experiments in rats and dogs using radio-labelled doxepin, show it to be well absorbed after oral administration, rapidly distributed to various tissues including liver, kidney, lung and brain, and rapidly metabolised by pathways similar to amitriptyline and imipramine. About 50 to 60 % of an oral dose was excreted in the urine in 24 hours. In a preliminary study in elderly patients, therapeutic plasma levels of total drug (doxepin plus desmethyldoxepin) appeared to be about 110ng/ml, and were associated with a dose range of 50 to 300mg daily. Another study in depressed patients suggests that clinical response correlates with plasma levels of desmethyldoxepin of 20ng/ml or above, but not with plasma levels of doxepin alone.
Therapeutic trials: When confounding effects due to study population differences are eliminated and the similar overall response rate in uncontrolled and comparative trials is taken into account, together with the superior results of doxepin over a placebo, one must conclude that doxepin is an active antidepressant. Whether it is definitely as effective overall as amitriptyline and imipramine in depression must await clarification in studies involving a large number of patients. Trials involving relatively small numbers of patients in wellmatched treatment groups have not been able to detect a statistically significant overall difference between doxepin and amitriptyline or imipramine. Nevertheless, trends for differences in certain types of depression have emerged. From both the comparative trials and the clinical experience in uncontrolled trials, doxepin seems to have mood elevating activity probably less marked than that of imipramine but similar to that of amitriptyline. Thus in the largest uncontrolled trial doxepin was most effective in agitated depressives and of lesser benefit in retarded depressives. In the largest comparative trial, doxepin tended to be more effective than imipramine in neurotic depression, while imipramine was more effective in endogenous depression. Doxepin also tends to be more effective than imipramine in depressed patients with sleep disturbances. Similar differences between doxepin and amitriptyline have been less evident, possibly because both have mood elevating properties as well as pronounced sedative activity. Doxepin cannot be regarded as superior to other tricyclic antidepressants in the treatment of severe, endogenous depressions.
It is possible that doxepin may have a more prominent sedative effect than amitriptyline because in general, doxepin has tended to produce a more favorable response than amitriptyline in patients with depression associated with anxiety or the mixed depression-anxiety syndrome. Doxepin has achieved a similar response as amitriptyline-perphenazine in these patients, but appears to be better tolerated. The antianxiety effect of doxepin occurs earlier than its antidepressant effect, and more rapidly than that of amitriptyline or amitriptylineperphenazine. The onset of antidepressant effect of doxepin is similar to that of amitriptyline or amitriptyline-perphenazine, but in some studies was less rapid than that of imipramine. Preliminary findings suggest that the onset of antidepressant effect of doxepin may be more rapid with a single daily bedtime dosage regimen than with a divided daily dose schedule.
In preliminary studies, doxepin appears to have a lesser depressive effect on intracardiac conduction than imipramine or amitriptyline. It has been well tolerated by patients with myocardial disease, although patient numbers have not been very large, and by the elderly in whom postural hypotension and anticholinergic side-effects have not proved a problem.
The effects of doxepin in anxiety states are not such that it can be considered in preference to the benzodiazepines, but when a predominant anxiety state is accompanied by depression, doxepin has proved superior to chlordiazepoxide and diazepam and to be associated with a much smaller incidence of ataxia.
Side-effects are generally mild and tend to disappear with continued treatment, or if necessary, reduction of dosage. The most common side-effects have been dry mouth, drowsiness, constipation and dizziness. Excessive daytime drowsiness or sedation can be overcome by giving the major portion or the total daily dose at bedtime. Other side-effects are typical of tricyclic antidepressants and have occurred much less frequently. Hypotension and tachycardia in particular have been uncommon with doxepin. The usual precautions for use of tricyclic antidepressants also apply to doxepin.
Doxepin has only a moderate effect on the norepinephrine pump. Consequently, only at doses of 200mg or more daily has it antagonised the antihypertensive effect of guanethidine or bethanidine. In cases where doxepin has antagonized the antihypertensive effect of guanethidine or bethanidine, and the blood pressure has returned to pretreatment hypertensive levels, abrupt withdrawal of doxepin has been followed by a rebound increase in diastolic pressure to dangerously high levels above the pretreatment value.
Dosage should be individualised. The usually effective dosage for most depressed patients has been 75 to 150mg daily for outpatients and 150 to 300mg daily for hospitalised patients. A few patients have required larger doses. Doses for the elderly should be smaller initially, with smaller progressive increases. Patients with anxiety have usually been treated with 75 to 150mg daily, but hospitalised patients and some other patients may require larger doses. A dosage regimen based on the major portion or total daily dose given at bedtime has been of benefit in depressed patients with sleep disturbances, in the elderly and when it has been necessary to avoid any excessive daytime drowsiness. Dosage increases of tricyclic antidepressants should always be gradual, particularly in bedtime-based schedules.
Similar content being viewed by others
References
Aceto, M.D.: The antinicotinic effects of drugs with clinically useful sedative-antianxiety properties. Pharmacology 13: 458 (1975)
Avery, G.S.: Guide to clinically significant drug interactions, p.936, 938. Drug Treatment: Principles and Practice of Clinical Pharmacology and Therapeutics (ADIS Press, Sydney; Publishing Sciences Group, Boston; Churchill Livingstone, Edinburgh 1976)
Alix, B.: Etude en double aveugle de la doxepin et d’un anxiolytique d’utilisation courante en therapeutique cardiologique. Medicine et Hygiene 27: 1425 (1969)
Ayd, F.J.: A clinical evaluation of doxepin (Sinequan). Diseases of the Nervous System 30: 396 (1969)
Ayd, F.J.: Long-term administration of doxepin (Sinequan). Diseases of the Nervous System 32: 617 (1971)
Ayd, F.J.: Doxepin with other drugs. Southern Medical Journal 66: 465(1973)
Ayd, F.J.: Single daily dose of antidepressants. Journal of the American Medical Association 230: 263 (1974)
Ayd, F.J.: Central anticholinergic activity and tricyclic antidepressant efficacy. International Drug Therapy Newsletter 10: 21 (1975a)
Ayd, F.J.: Maintenance doxepin (Sinequan) therapy for depressive illness. Diseases of the Nervous System 36: 109 (1975b)
Bacal, B.; Amarilhodo, I.P.; Zamijevski, M. and Lion, M.F.: Doxepin action on neurotic patients with cardiac symptomatology. Hospital 76: 1733(1969)
Ban, T.A.: A comparative clinical and conditioning study with doxepin and diazepam in psychoneurotic patients. Personal communication (1976)
Barth, N.; Manns, M. and Muscholl, E.: Arrhythmias and inhibition of noradrenaline uptake caused by tricyclic antidepressants and chlorpromazine on the isolated perfused rabbit heart. Naunyn-Schmiedeberg’s Archives of Pharmacology 288: 215 (1975)
Barth, N. and Muscholl, E.: The effects of the tricyclic antidepressants desipramine, doxepin and iprindole on the isolated perfused rabbit heart. Naunyn-Schmiedeberg’s Archives of Pharmacology 284: 215(1974)
Bauer, G. and Nowak, H.: Doxepin, a new antidepressant: Comparison of activity with amitriptyline. Arzneimittel-Forschung 19: 1642(1969)
Beaubien, J.; Ban, T.A.; Lehmann, H.E. and Jarrold, L.: Doxepin in the treatment of psychoneurotic patients. Current Therapeutic Research 12: 192 (1970)
Beber, C. and Georgia, E.H.: Before ECT — A psychopharmacological approach to the treatment of the clinically depressed geriatric patient. Presented at the American Geriatrics Society Annual Meeting April 16–17 (Miami, Florida 1975)
Belsasso, G.; Lara Tapia, H. and Grajales, A.: Clinical investigation with doxepin, a new antidepressant. Current Therapeutic Research 11: 165(1969)
Bergener, M. and Behrends, K.: Zur klinischen Prufung von Doxepin, einer neuartigen antidepressiv wirksamen Substanz. Arzneimittel-Forschung 16: 1617(1966)
Bianchi, G.N.; Barr, R.F. and Kiloh, L.G.: A comparative trial of doxepin and amitriptyline in depressive illness. Medical Journal of Australia 1: 843(1971)
Bianchi, G.N. and Phillips, J.: A comparative trial of doxepin and diazepam in anxiety states. Psychopharmacologia 25: 86 (1972)
Bickel, M.H.: Poisoning by tricyclic antidepressant drugs. General and pharmacokinetic considerations. International Journal of Clinical Pharmacology 11: 145 (1975)
Blaine, G.: Double-blind comparison of doxepin and amitriptyline in depressed menopausal outpatients receiving estrogen replacement therapy; in Mendels (Ed.) Sinequan: A monograph of recent studies, p.43 (Excerpta Medica, Amsterdam 1975)
Bohlau, V.; Schildwuchter, G. and Bohlau, E.: Doxepin in der praklinischen geriatric Medizinische Monatsschrift 26: 422 (1972)
Boysen, K.H.; Hackl, H. and Lackner, M.: Double-blind trial with doxepin and opipramol in patients with vegetative depressive symptoms. Praxis 59: 1242 (1970)
Brogden, R.N.; Speight, T.M. and Avery, G.S.: Doxepin. A review. Drugs 1: 194 (1971)
Buczko, W.; De Gaetano, G. and Garattini, S.: Influence of some tricyclic antidepressive drugs on the uptake of 5-hydroxytryptamineby rat blood platelets. Journal of Pharmacy and Pharmacology 26: 814(1974)
Bukowczyk, A. et al.: Study of the antidepressant activity of doxepin (Sinequan). Preliminary report. Psychiatria Polska 2: 197 (1971)
Burrows, G.D.; Mowbray, R.M. and Davies, B.: A sequential comparison of doxepin (Sinequan) and placebo in depressed patients. Medical Journal of Australia 1: 364 (1972)
Burrows, G.D.; Vohra, J.; Hunt, D.; Sloman, J.G.; Scoggins, B.A. and Davies, B.M.: The effects on the heart of different tricyclic antidepressants. Presented at the Royal College of Psychiatrists, London, July (1975)
Burrows, G.D.; Vohra, J.; Hunt. D.; Sloman, J.G.; Scoggins, B.A. and Davies, B.: Cardiac effects of different tricyclic antidepressant drugs. British Journal of Psychiatry 129: 335 (1976a)
Burrows, G.D.; Vohra, J.; Dumovic, P.; Maguire, K.; Scoggins, B.A. and Davies, B.: Tricyclic antidepressant drugs and cardiac conduction. Progress in Neuro-Psychopharmacology. In press (1976b)
Butterworth, A.T. and Watts, R.D.: Treatment of hospitalised alcoholics with doxepin and diazepam. A controlled study. Quarterly Journal of Studies on Alcohol 32: 78 (1971)
Castrogiovanni, P.; Placidi, G.F.; Maggini, C; Ghetti, B. and Cassano, G.B.: Clinical investigation of doxepin in depressed patients. Pilot open study, controlled double-blind trial versus imipramine, and all-night polygraphic study. Pharmakopsychiatrie Neuro-Psychopharmakologie 4: 170 (1971)
Chaplan, A.: Doxepin in anxious/depressed outpatients with gastrointestinal symptoms: Double-blind comparison of doxepin and perphenazine/amitriptyline; in Mendels (Ed.) Sinequan: A monograph of recent clinical studies, p.32 (Excerpta Medica, Amsterdam 1975)
Charatan, F.B.: Depression in old age. New York State Journal of Medicine 75: 2505(1975)
Chaudhry, M.R.; Ishaq, M. and Suleman, M.: Double blind study with sinequan (doxepin) vs diazepam vs placebo in psychoneurosis. Journal of the Pakistan Medical Association 20: 315(1970)
Chien, C.P.; Stotsky, B.A. and Cole, J.O.: Psychiatric treatment for nursing home patients — drug, alcohol and milieu. American Journal of Psychiatry 130: 543 (1973)
Ciurezu, T. and Timofte, G.: Doxepin therapy in outpatients with depressive anxious states. Revue Roumaine Medicale 12: 143 (1974)
Clark, C.J. and Downie, C.C.: A method for the rapid determination of the number of patients to include in a controlled clinical trial. Lancet 2: 1357(1966)
Coleman, J.: Severe emotional disturbance associated with physical illness. I. Double-blind study. Psychosomatics 10 (Section II): 32 (1969)
Constantine, J.W.; Scriabine, A.; Smith, S.G.; McShane, W.K. and Booker, Katherine D.: Antispasmodic and vasodilator activities of doxepin. Journal of New Drugs 4: 249 (1964)
Coppen, A.; Gupta, R.; Montgomery, S.; Ghose, K.; Bailey, J.; Burns, B. and De Ridder, J.J.: Mianserin hydrochloride: A novel antidepressant. British Journal of Psychiatry 129: 342 (1976)
Davies, B.; Burrows, G.D.; Dumovic, P.; Vohra, J.; Hunt, D.; Sloman, G. and Scoggins, B.: Effects on the heart of different tricyclic antidepressants; in Mendels (Ed) Sinequan: A monograph of recent clinical studies, p.54 (pmExcerpta Medica, Amsterdam 1975)
d’Elia, G.; von Knorring, L.; Marcusson, J.; Mattsson, B.; Perris, C. and Persson, G.: A double-blind comparison between doxepin and diazepam in the treatment of states of anxiety. Acta Psychiatrica Scandinavica Suppl. 255: 35 (1974)
Denber, H.C.; Boone, W.F. and Tuchman, M.M.: High versus low dose doxepin in depressed patients: A controlled study; in Mendels (Ed) Sinequan: A monograph of recent clinical studies, p.59 (Excerpta Medica, Amsterdam 1975)
Diehl, L.W.: On the treatment of depressive syndrome with doxepin in the hospital. Medizinische Welt 45: 1805 (1971)
Downing, R.W. and Rickeis, K.: Mixed Anxiety-depression. Archives of General Psychiatry 30: 312 (1974)
DuBois, R.: A trial of doxepin in the treatment of the anxietydepression-somatization complex in internal medicine: A study of 32 cases. Medicine et Hygiene 27: 1428 (1969)
Ducluzeau, R.: Les intoxications a la doxepine. Bulletin de Medicine Legale et de Toxicologie Medicale 16: 281 (1973)
Dufficy, R.G.: Use of psychotherapeutic drugs in the acute detoxification of heroin addicts. Military Medicine 138: 748 (1973)
Dunleavy, D.L.F.; Brezinova, V.; Oswald, I.; MacLean, A.W. and Tinker, M.: Changes during weeks in effects of tricyclic drugs on the human sleeping brain. British Journal of Psychiatry 120: 663(1972)
Ebie, J.C.: Doxepin and a combination of amitriptyline and chlordiazepoxide in the treatment of anxiety-depression syndrome — A double-blind trial. Ghana Medical Journal 13: 33 (1974)
Elonen, E.: Correlation of the cardiotoxicity of tricyclic antidepressants to their membrane effects. Medical Biology 52: 415–423(1974)
Elonen, E.: Effect of β-adrenoreceptor blocking drugs, physostigmine, and atropine on the toxicity of doxepin in mice. Medical Biology 53: 231 (1975)
Elonen, E.; Linnoila, M.; Lukkari, I. and Mattila, M.J.: Concentration of tricyclic antidepressants in plasma, heart and skeletal muscle after their intravenous infusion to anaesthetized rabbits. Acta Pharmacologica et Toxicologica 37: 274(1975)
Elonen, E.; Mattila, M.J. and Saarnivaara, L.: Cardiovascular effects of amitriptyline, nortriptyline, protriptyline and doxepin in conscious rabbits. European Journal of Pharmacology 28: 178(1974)
Elonen, E. and Mattila, M.J.: Cardiovascular effects of amitriptyline, nortriptyiine, protriptyline and doxepin in conscious rabbits after sub-acute pretreatment with protriptyline. Medical Biology 53: 238(1975)
Elwan, O.; Taher, Y.; Allam, M. and Hassan, M.A.: A comparative study of antidepressants in the treatment of depressive states. Journal of International Medical Research 4: 202 (1976)
Evans, W.; Gensler, F.; Blackwell, B. and Galbrecht, C: The effects of antidepressant drugs on pain relief and mood in the chronically ill. A double-blind study, Psychosomatics 14: 214 (1973)
Fann, W.E.; Cavanaugh, J.H.; Kaufmann, J.S.; Griffith, J.D.; Davis, J.M.; Janowsky, D.S. and Oates, J.A.: Doxepin: Effects on transport of biogenic amines in man. Psychopharmacologia 22: 111 (1971)
Fann, W.E.; Davis, J.M.; Janowsky, D.S.; Kaufmann, J.S.; Cavanaugh, J.H. and Oates, J.A.: Effect of antidepressant and antimanic drugs on amine uptake in man. Journal of Nervous and Mental Disease 158: 361 (1974)
Fielding, J.M.; Mowbray, R.M. and Davies, B.: Trial of an antianxiety compound — doxepin (‘Sinequan’). Psychopharmacologia 15: 134 (1969a)
Fielding, J.M.; Mowbray, R.M. and Davies, B.: A preliminary controlled study of doxepin (‘Sinequan’) as an antianxiety drug. Medical Journal of Australia 2: 851 (1969b)
Forsen, A.: Doxepin in the treatment of climacteric symptoms. A double-blind pilot study. Current Medical Research and Opinion 2(Suppl.): 51 (1975)
Friedel, R.O. and Raskind, M.A.: Relationship of blood levels of Sinequan to clinical effects in treatment of depression in aged patients; in Mendels (Ed) Sinequan: A monograph of recent clinical studies, p.51 (Excerpta Medica, Amsterdam 1975)
Gabay, S.; King, P. and Achee, F.M.: Characteristics of MAO activity in purified brain mitochondria with reference to the question of multiple forms. Presented at the 5th International Meeting of the International Society for Neurochemistry, Barcelona, Spain (1975)
Gallant, D.M.; Bishop, M.P.; Guerrero-Figueroa, R.; Selby, M. and Phillips, R.: Doxepin versus diazepam: A controlled evaluation in 100 chronic alcoholic patients. Journal of Clinical Pharmacology 9: 57 (1969)
Garcia-Torres, F.: Preliminary experience with doxepin (P-3693-A), in the treatment of depression. Actualidad Medica 517: 23 (1968)
General Practitioner Research Group: A comparison between dothiepin and doxepin in the treatment of depression. Practitioner 216: 581 (1976)
Gerson, I.M.; Friedman, R. and Unterberger, H.: Non-antagonism of antiadrenergic agents by a dibenzoxepine (Preliminary Report). Diseases of the Nervous System 31: 780 (1970)
Gillmer, R.E.: Treatment of the depressive reaction: A clinical evaluation of a new psychotherapeutic drug, doxepin (Sinequan). South African Medical Journal 44: 1386 (1970)
Glick, B.S.: Comparison of doxepin and thioridazine in outpatients. Diseases of the Nervous System 34: 37 (1973)
Glowinski, J. and Axelrod, J.: Effect of drugs on the uptake, release and metabolism of H3-norepinephrine in the rat brain. Journal of Pharmacology and Experimental Therapeutics 149: 43(1965)
Goldberg, H.L. and Finnerty, R.J.: The use of doxepin in the treatment of symptoms of anxiety neurosis and accompanying depression: A collaborative controlled study. American Journal of Puychiatry 129: 74 (1972a)
Goldberg, H.L. and Finnerty, R.J.: Depression/anxiety sleep. Presented at the Annual Meeting of the Massachusetts Medical Society, Boston, Massachusetts, May (1972b)
Goldberg, H.L. and Finnerty, R.J.: Evaluation of h.s. versus t.i.d. dosage in the treatment of clinical depression/anxiety with accompanying sleep disturbances. Presented at Glover Memorial Hospital, Massachusetts, April (1973)
Goldberg, H.L.; Finnerty, R.J. and Cole, J.O.: Doxepin: Is a single daily dose enough? Amer. J. Psych. 131: 1027 (1974a)
Goldberg, H.L.; Finnerty, R.J.; Nathan, L. and Cole, J.O.: Doxepin in single bedtime dose in psychoneurotic outpatients. Archives of General Psychiatry 31: 513 (1974b)
Goldberg, H.L.; Finnerty, R.J. and Cole, J.O.: The effect of doxepin in the aged: Interim report on memory changes and EKG findings; in Mendels (Ed) Sinequan: A monograph of recent clinical studies, p.65 (Excerpta Medica, Amsterdam 1975a)
Goldberg, H.; Finnerty, R.; Cole, J. and Rickeis, K.: Collaborative studies in private practice. Comparison of doxepin and imipramine. Presented at the American College of Neuropsychopharmacology Meeting, Puerto Rico, Dec. 1975 (1975b)
[Also reported by Goldberg, Finnerty and Rickels, unpublished data, Pfizer Laboratories 1976].
Goldstein, B.J. and Pinosky, D.G.: Clinical evaluation of doxepin in anxious depressed outpatients. Current Therapeutic Research 11: 169 (1969)
Goldstein, B.J.; Brauzer, B.; Steinbook, R.M. and Jacobson, A.F.: Psychotropic drug treatment of mixed anxiety and depression in non-psychiatric office patients: Expected and unexpected findings comparing doxepin, chlordiazepoxide and placebo. Southern Medical Journal 66: 892 (1973)
Gomez-Martinez, I.: Preliminary double-blind clinical trial with a new antidepressive, doxepin. Current Therapeutic Research 10: 116(1968)
Gomez-Martinez, I.: Preliminary double-blind comparative study with doxepin and chlordiazepoxide in the treatment of anxiety. Munchener Medizinische Wochenschrift (Spanish Edition) 4: 391 (1970)
Gomide, C.H.A.: Clinical experience with doxepin. A double-blind study: Doxepin vs placebo. Folha Med 59: 553 (1969)
Gonzalez, J.V.: Comparative experience in the use of doxepin. Revue Medico Cirugia 33(6): 246–250 (1967)
Grof, R.; Saxena, B.; Cantor, R.; Daigle, L.; Hetherington, D. and Haines, T.: Doxepin versus amitriptyline in depression. A sequential double-blind study. Current Therapeutic Research 16: 470(1974)
Guzman-Vilar, T.: Comparative experience with doxepin, chlordiazepoxide and placebo in neurovegetative problems. Revista Medicina y Cirugia (Colombia) 33: 105 (1969)
Hackett, Elizabeth; Gold, R.L.; Kline, N.S. and Winick, L.: Controlled evaluation of psychotropic drugs in a private psychiatric practice. Psychosomatics 8: 162 (1967)
Hackett, Elizabeth and Kline, N.S.: Antidepressant activity of doxepin and amitriptyline. A double-blind evaluation. Psychosomatics 10 (Section II): 21 (1969)
Haider, I.: A comparative trial of doxepin and amitriptyline in cases of depressive illness. Journal of the Pakistan Medical Association 21: 353(1971)
Hano, J.; Sowinska, H. and Baran, L.: Central action of doxepin. Dissertationes Pharmaceutica et Pharmacologica 24: 415 (1972)
Hart, F.D.: Rheumatic disorders; in Avery (Ed) Drug Treatment, p.624 (ADIS Press, Sydney; Publishing Sciences Group, Acton; Churchill Livingstone, Edinburgh 1976)
Hasan, K.Z. and Akhtar, M.I.: Double-blind clinical study comparing doxepin and imipramine in depression. Current Therapeutic Research 13: 327 (1971)
Haslam, M.T.: A comparative trial of lorazepam and doxepin in the treatment of anxiety. Current Medical Research and Opinion 2: 240(1974)
Hecht, Y.: A double-blind trial of doxepin and a commonly used anxiolytic in patients in a gastroenterologic survey. Medicine et Hygiene 27: 1427(1969)
Hobbs, D.C.: Distribution and metabolism of doxepin. Biochemical Pharmacology 18: 1941 (1969)
Hollanda, L.; da Silva, C.N.A.; Lira, B.S., and Ferreira, S.C.: A double-blind clinical study with a new psychotropic doxepin vs placebo. O Hopital 77: 59 (1970)
Hollister, L.E.: Doxepin hydrochloride (Drugs five years later). Annals of Internal Medicine 81: 360 (1974)
Israel, L.; Michel, D.; Weil, J. and Wysoki, V.: Doxepin and librium. Annales Medico-Psychologiques 3: 465–469 (1970)
Jefferson, J.W.: A review of the cardiovascular effects and toxicity of tricyclic antidepressants. Psychosomatic Medicine 37: 160 (1975)
Johnstone, E.E. and Claghorn, J.L.: Doxepin versus chlordiazepoxide. A controlled comparison in neurotic outpatients. Current Therapeutic Research 10: 514(1968)
Jones, B.L.; Eastgate, N.O.; Downey, P.G. and Davies, L.J.H.: A comparison of doxepin with diazepam and amitriptyline in general practice. New Zealand Medical Journal 76: 174 (1972)
Joost, H.G.; Poser, W. and Panten, U.: Inhibition of insulin release from the rat pancreas by cyproheptadine and tricyclic antidepressants. Naunyn-Schmiedeberg’s Archives of Pharmacology 285: 99 (1974)
Kales, A.; Dement, W.G.; Tan, TL.; Zarcone, V.; Hoddes, E.; Carshadan, M. and Kales, J.D.: Effects of Sinequan on sleep of insomniac subjects. Psychophysiology 9: 93 (1972)
Kaneto, H.; Koida, M. and Tsuchie, F.: Studies on tolerance and physical dependence producing liability of doxepin. Folia Pharmacologica Japonica 68: 704 (1972)
Karacan, I.; Blackburn, A.B.; Thornby, J.I.; Okawa, M.; Salis, P. J. and Williams, R.L.: The effect of doxepin HCl (Sinequan) on sleep patterns and clinical symptomatology of neurotic depressed patients with sleep disturbance; in Mendels (Ed) Sinequan: A monograph of recent clinical studies, p.4 (Excerpta Medica, Amsterdam 1975)
Karacan, I. and Williams, R.L.: Advances in the pharmacology of sleep. Presented as a scientific exhibit at the 129th Annual Meeting of the American Psychiatric Association, Miami Beach, May (1976)
Karacan, I.; Williams, R.L. and Salis, P.J.: Sleep and sleep abnormalities in depression; in Fann, Karacan, Pokorny and Williams (Eds) Phenomenology and Treatment of Depression, p.167 (Spectrum, New York 1977)
Karobath, M.E.: Tricyclic antidepressive drugs and dopamine-sensitive adenylate cyclase from rat brain striatum. European Journal of Pharmacology 30: 159 (1975)
Kasich, A.M.: A controlled trial of doxepin and diazepam in the treatment of anxiety accompanying gastrointestinal disease. British Journal of Clinical Practice 23: 121 (1969a)
Kasich, A.M.: Clinical evaluation of doxepin and diazepam in patients with gastrointestinal disease and anxiety. A controlled double-blind study and long-term evaluation. Psychosomatics 10 (Section II): 18 (1969b)
Kiev, A.: The role of chemotherapy in managing potentially suicidal patients. Diseases of the Nervous System 35: 108 (1974)
Kimura, M.; Nakagawa, T.; Suehiro, K.; Kono, T.; Takayama, T. and Nagato, H.: A double-blind comparison of clinical efficacy of doxepin and imipramine in depressive patients. Presentation at International Congress of Psychosomatic Disease, Italy, August (1975)
Kimura, Y.; Kume, M. and Kageyama, K.: Absorption, distribution and metabolism of doxepin hydrochloride. Pharmacometrics 6: 955 (1972)
Kingstone, E.; Kolivakis, T. and Kossatz, I.: Doxepin versus chlordiazepoxide: A double-blind study on anxious outpatients. Current Therapeutic Research 12: 213 (1970)
Kishore, B.; Kaur, A. and Verma, R.S.: A comparative study of doxepin versus trifluoperazine in anxiety neurosis. Journal of the Indian Medical Association 60: 280 (1973)
Kline, N.S.; Cooper, T. and Johnston, B.: Doxepin and desmethyldoxepin serum levels and clinical response; in Gottschalk and Merlis (Eds) Pharmacokinetics of Psychoactive Drugs: Blood Levels and Clinical Response, p.221 (Spectrum, New York 1976)
Knott, D.H.; Beard, J.D. and Fink, R.D.: Alcoholism. The physician’s role in diagnosis and treatment. Presented as a scientific exhibit at the 125th Annual Meeting of the American Psychiatric Association, Dallas, May (1972)
Koe, B.K. and Constantine, J.W.: Blocking H3-norepinephrine uptake and some guanethidine-induced effects with tricyclic antidepressant drugs. Archives Internationales Pharmacodynamie et de Therapie 195: 71 (1972)
Koknel, O. and Eper, O.: A study with Sinequan (Doxepin). Diseases of the Nervous System 32: 405 (1971)
Krakowski, A.J.: Activity study of doxepin, a new antidepressant. Psychosomatics 9: 89 (1968)
Krakowski, A.J.: Biphasic drugs in the treatment of depression with anxiety. Psychosomatics 10 (Section II): 7 (1969)
Krasner, E.B.: Double-blind comparative trial of doxepin and chlordiazepoxide in general practice. British Journal of Clinical Practice 25: 555(1971)
Kulkarni, A.S. and Bocknik, S.E.: Interaction of Ro 4-1284 with doxepin, amitriptyline and desmethylimipramine on mouse avoidance behaviour. Europ. J. Pharmacol. 22: 59 (1973)
Laffranchini, S.: A double-blind comparative trial of Sinequan and Limbitrol. Medecine et Hygiene 29: 227 (1971)
Lang, W.R.: Trial of a new psychotropic drug, doxepin. New Zealand Medical Journal 72: 181 (1970)
Lassen, J.B.: The effect of p-chloroamphetamine on motility in rats after inhibition of monoamine synthesis, storage, uptake and receptor interaction. Psychopharmacologia 34: 243 (1974)
Lee, R.E.: The influence of psychotropic drugs on prostaglandin biosynthesis. Prostaglandins 5: 63 (1973)
Lingjaerde, O.: Effect of doxepin on uptake and efflux of serotonin in human blood platelets in vitro. Psychopharmacology 47: 183(1976)
Majczak, A.; Masiak, M.; Grzywa, Anna; Gorniewicz, Anna and Komada, Joanna: Zastrosowanie sinequanu w leczeniu roznych form klinicznych depresji. Psychiatria Polska 9: 51 (1975)
Marble, A.; Selenkow, H.A.; Rose, L.I.; Dluhy, R.G. and Williams, G.H.: Endocrine diseases; in Avery (Ed) Drug Treatment, p.422 (ADIS Press, Sydney; Publishing Sciences Group, Boston; Churchill Livingstone, Edinburgh 1976)
McLaughlin, B.: Management of psychoneurotic anxiety and depression in outpatients. Psychosomatics 10 (Section II): 28 (1969)
Mendels, J. and Hawkins, D.R.: Sleep and depression. Further considerations. Archives of General Psychiatry 19: 445 (1968)
Mendels, J. and Schless, A.: A controlled comparison of doxepin h.s. and doxepin q.i.d. Journal of Clinical Pharmacology 15: 534 (1975)
Miletto, G.: La doxepine en pratique psychiatrique. Doses fortes — cures prolongees. Psychologie Medicale 4: 805 (1972)
Milner, G. and Landauer, A.A.: The effects of doxepin, alone and together with alcohol, in relation to driving safety. Medical Journal of Australia 1: 837 (1973)
Mises, R. and Moniot, M.: Double-blind comparative study of doxepin and medazepam in adolescents. Annales Medico-Psychologiques 129: 431 (1971)
Mivelaz, M.: Doxepin in psychiatric out-patients. Medecine et Hygiene 27: 1425 (1969)
Molinengo, L. and Ricci-Gamalero, S.: The action of imipramine, amitriptyline, doxepin and butriptyline in an operant conditioning schedule. Psychopharmacologica 24: 247 (1972)
Montgomery, B.A.; Cullinan, T.R. and Bayley, A.J.: A double-blind comparative trial of doxepin hydrochloride and chlordiazepoxide in anxiety and depression in general practice. British Journal of Clinical Practice 24: 207 (1970)
Moore, R.H. and White, R.P.: Central anticholinergic actions of doxepin in rabbits. Archives Internationales Pharmacodynamie et de Therapie 213: 113 (1975)
Moser, A.: Doxepin in geriatrics. Medecine et Hygiene 27: 1425 (1969)
Mundo, A.S.; Bonaccorsi, A.; Bareggi, S.R.; Franco, R.; Morselli, P.L.; Riva, E. and Garattini, S.: Relationships between tricyclic antidepressant concentrations, I-3H-noradrenaline uptake and chronotropic effect in isolated rat atria. European Journal of Pharmacology 28: 368 (1974)
Muratorio, A.; Maggnini, C. and Murri, L.: Effects of P-3693-A on night sleep of depressed subjects. Neuropsichiatria 33: 179 (1967)
Naftulin, D.H. and Ware, J.E.: A behavioral and clinical evaluation of two psychotropic agents: Doxepin-hydrochloride and perphenazine-amitriptyline hydrochloride. Psychosomatics 13: 125(1972)
Nahunek, K.; Kamenicka, V.; Ceskova, E.; Rodova, A.; Svestka, J. and Misurek, J.: Clinical experience with doxepin. Activitas Nervosa Superior 16: 185(1974)
Nixon, D.D.: Thrombocytopenia following doxepin treatment. Journal of the American Medical Association 220: 418 (1972)
Noguchi, Y.; Sakai, T.; Ishiko, J. and Sugimoto, S.: Acute toxicity of doxepin hydrochloride. Pharmacometrics (Tokyo) 6: 889–897 (1972a)
Noguchi, Y.; Sakai, T. and Arakawa, M.: Subacute toxicity of doxepin hydrochloride in rats. Pharmacometrics (Tokyo) 6: 899–928 (1972b)
Noguchi, Y.; Sakai, T. and Arakawa, M.: Chronic toxicity of doxepin hydrochloride in rats. Pharmacometrics (Tokyo) 6: 929–954 (1972c)
Norheim, G.: Determination of doxepin in autopsy material. Archiv für Toxikologie 31: 7 (1973)
Nurowska, K. and Welbel, L.: Efficacy of dibenzepin, doxepin, and chlorimipramine in depression. Psychiatrie Polska 7: 69–74(1973)
Oates, J.A.; Fann, W.E. and Cavanaugh, J.H.: Effect of doxepin on the norepinephrine pump. A preliminary report. Psychosomatics 10 (Section II): 12 (1969)
Oliver, J.S. and Watson, A.A.: Doxepin poisoning. Medicine, Science, and the Law 14: 280 (1974)
Otsuki, I.; Ishiko, J.; Sakai, M.; Shimahara, K. and Momiyama, T.: General pharmacological effects of doxepin hydrochloride: A psychotropic agent. Folia Pharmacologia Japonica 68: 762 (1972a)
Otsuki, I.; Ishiko, J. and Sakai, M.: Comparison of the pharmacologic activities of doxepin hydrochloride with those of its geometric isomers. Pharmacometrics (Tokyo) 6: 973–984 (1972b)
Owaki, Y.; Momiyama, H. and Onodera, N.: Effects of doxepin hydrochloride administered to pregnant rats upon the fetuses and their postnatal development. Pharmacometrics 5: 913 (1971)
Pebay-Peyroula, F.; Bismuth, C. and Autret, A.: Premier cas francais d’intoxication aigue par la doxepin. Journal European de Toxicologie 2: 77(1969)
Pereira, C.J.L. and Lipke, C.P.R.: Preliminary results from an eight months trial of a single agent — doxepin/electroencephalographic study of 32 patients. Folha Medica (Brazil) 60: 51 (1970)
Pitts, N.E.: The clinical evaluation of doxepin — a new psychotherapeutic agent. Psychosomatics 10: 164(1969)
Poeldinger, W.: Zur Methodik der Entwicklung und Prufung neuer Antidepressiva. Der Nervenarzt 37: 121 (1966a)
Poeldinger, W.: Vergleichende klinische Erfahrungen mit neuen trizykuschen Psychopharmaka. Therapeutische Umschau 23: 373 (1966b)
Poeldinger, W. and Peter, J.: Wirkungsspektren und Indikationen des Doxepins. Praxis 59: 1006 (1970)
Poeldinger, W.; Angst, J.; Cornu, F.; Dick, P. and Heimann, J.: Therapeutische Erfahrungen an funf Kliniken mit einen Dibenzoxepin — Derivat bei depressionen Zustandsbilden. Arzneimittel-Forschung 16: 650(1966)
Popovic, M. et al.: Our experiences with doxepin in the treatment of depressive states. Anal. Zavoda Mentalno Zdravlje (Belgrade) 2: 25(1970)
Prange, A.J.: The use of antidepressant drugs in the elderly patient; in Eisdorfer and Fann (Eds) Psychopharmacology and Aging, p.224 (Plenum, New York 1973)
Querol, M.: Double blind study with antl-depressants. Revista de Neuro-Psiquiatria 33: 251 (1970)
Radmayr, E.: Attempted suicide with doxepin. Osterreich Monatschafte fur azztliche Fortbildung und pharmazeutische Dokumentation 12: 155(1971)
Radmayr, E.: Langzeittherapie mit Sinquan. Medizinische Welt 27: 446(1976)
Rapado, A.: Double blind clinical trial of doxepin and placebo in a general medical clinic. Medicine et Hygiene 27: 1426 (1969)
Raskind, M.A.; Alvarez, C; Pietrzyk, M.; Westerlund, K. and Herlin, S.: Helping the elderly psychiatric patient in crisis. Geriatrics 6: 51 (1976)
Renshaw, D.C.: Doxepin treatment of sexual dysfunctions associated with depression; in Mendels (Ed) Sinequan: A monograph of recent clinical studies, p.23 (Excerpta Medica, Amsterdam 1975)
Ribbentrop, A. and Schaumann, W.: Pharmakologische Untersuchungen mit Doxepin, einem Antidepressivum mit zentral anticholinerger und sedierender Wirkung. Arzneimittel-Forschung 15: 863 (1965)
Rickeis, K.; Hutchison, J.C.; Weise, C.C.; Csanalosi, Irma; Chung, H.R. and Case, W.G.: Doxepin and amitriptylineperphenazine in mixed anxious-depressed neurotic outpatients. A collaborative controlled study. Psychopharmacologia 23: 305(1972)
Rickels, K.; Perloff, M; Stepansky, W.; Dion, H.S.; Case, W.G. and Sapra, R.K.: Doxepin and diazepam in general practice and hospital clinic neurotic patients. A collaborative controlled study. Psychopharmacologia 15: 265 (1969)
Roth, J.A.: Inhibition of rabbit monoamine oxidase by doxepin and related drugs. Life Sciences 16: 1309 (1975)
Ruiz Taviel de Andrade, A.: Twenty-five cases of anxiety/ depression treated with doxepin hydrochloride. Revista Medicina(Mex) 51: 164(1971)
Saarnivaara, L. and Mattila, M.J.: Comparison of tricyclic antidepressants in rabbits: Antinociception and potentiation of the noradrenaline pressor responses. Psychopharmacologia 35: 221 (1974)
Sanger, M.D.: The treatment of anxiety and depression in the allergic patient. Annals of Allergy 27: 506 (1969a)
Sanger, M.D.: Depression and allergic dermatologic disease. Psychosomatics 10 (Section II): 25 (1969b)
Schaumann, Von, W. and Ribbentrop, A.: Interferenz der zentralen anticholinergen Wirkung bei der tierexperimentellen Prufung potentieller Antidepressiva. Arzneimittel Forschung 16: 646(1966)
Schildkraut, J.J.: Neuropsychopharmacology and the Affective Disorders (Little Brown, Boston 1970)
Schreiber, F.K.: Doxepin in functional heart complaints and other organic diseases. Medizinische Klinik 65: 1920 (1970)
Seppala, T.; Linnoila, M.; Elonen, E.; Mattila, M.J. and Maki, M.: Effect of tricyclic antidepressants and alcohol on psychomotor skills related to driving. Clinical Pharmacology and Therapeutics 17: 515 (1975)
Silva, G.R. and Signes, G.E.: Evaluacion clinica de la doxepina en pacientes con reaccion depresiva (Experiencia doble-ciego). Revista Medica de Chile 100: 257 (1972)
Sim, M.; Bindman, E.; Conochie, B.C. and Sandilands, D.W.I.M.: The treatment of anxiety /depressive states. A comparative trial of doxepin (Sinequan) with chlordiazepoxide (Librium). Clinical Trials Journal 1: 22 (1971)
Simeon, J.; Spero, M. and Fink, M.: Clinical and EEG studies of doxepin. Psychosomatics 10 (Section II): 14 (1969)
Simeon, J.; Spero, M.; Nikolovksi, O.T. and Fink, M.: A comparison of doxepin and chlordiazepoxide in the therapy of anxiety. Current Therapeutic Research 12: 201 (1970)
Simpson, F.O.: Hypertensive disease; in Avery (Ed) Drug Treatment, p.500 (ADIS Press, Sydney; Publishing Sciences Group, Acton, Mass., Churchill Livingstone, Edinburgh 1976)
Smith, A.; Traganza, E. and Harrison, G.: Studies on the effectiveness of antidepressant drugs. Psychopharmacology, Special Issue; Psychopharmacology Research Branch, National Institute of Mental Health, Chevy Chase, March (1969)
Smith, J.A. and Renshaw, D.C.: Insomnia, a signal symptom. Presented at the 127th Annual Meeting of the American Psychiatric Association, Detroit, May (1974)
Smith, M.E.: A controlled comparative study of doxepin and chlordiazepoxide in psychoneurotic anxiety. Journal of Clinical Pharmacology 11: 152 (1971)
Solis, H.G.; Molina, G.B. and Pineyro, A.: Clinical evaluation of doxepin and amitriptyline in depressed patients. Current Therapeutic Research 12: 524 (1970)
Spaulding, P.E.: Pseudodementia in the nursing home. Scientific exhibit. Pfizer Laboratories (1976)
Spensley, J.: Doxepin: A useful adjunct in the treatment of heroin addicts in a methadone programme. International Journal of The Addictions 11: 191 (1976)
Steen, S.N. and Thomas, J.S.: The effects of doxepin, separately and combined with meperidine, on the human respiratory centre. IRCS Medical Science 1: 3 (1973)
Sterlin, C; Ban, T.A.; Lehmann, H.E. and Jarrold, L.: A comparative evaluation of doxepin and chlordiazepoxide in the treatment of psychoneurotic outpatients. Current Therapeutic Research 12: 195(1970)
Sterlin, C; Oliveros, R.; Ban, T.A. and Jarrold, L.: Doxepin in the treatment of psychoneurotic inpatients. Current Therapeutic Research 13: 580(1971)
Sterlin, C; Ban, T.A. and Jarrold, L.: The place of doxepin among the anxiolytic-sedative drugs. Current Therapeutic Research 14: 195 (1972a)
Sterlin, C; Ban, T.A.; Lehmann, H.E. and Jarrold, L.: Doxepin in the treatment of hospitalised and ambulatory psychoneurotic patients. International Journal of Clinical Pharmacology 6: 256 (1972b)
Souza, A.D.: Double blind study of doxepin in anxiety. A Folha Medica 62: 105(1971)
Tadokoro, S.: Behavioral-pharmacological studies on doxepin, a tricyclic psychotropic agent. 1. Changes of conditioned behavior after a single dose of doxepin. Folia Pharmacologica Japonica 68: 536 (1972a)
Tadokoro, S.: Behavioral-pharmacological studies on doxepin, a tricyclic psychotropic agent. 2. Changes of conditioned behavior after repeated doses of doxepin. Folia Pharmacologica Japonica 68: 548 (1972b)
Tehrani, J.B.; Rossi, G.V. and Goldstein, F.J.: Doxepin and imipramine: Effect on catecholamine inhibition of ganglionic transmission. Life Sciences 17: 257 (1975)
Toru, M.; Takamizawa, M.; Kariya, T.; Kobayashi, K. and Takahashi, R.: A double-blind sequential comparison of doxepin with amitriptyline in depressed patients. Psychosomatics 13: 241 (1972)
Traitz, J.J.; Blaine, G. and Georgia, E.H.: Evaluation of gastrointestinal symptomatology in psychoneurotically depressed outpatients. Presented at the Southern Medical Association, 79th Annual Meeting, New Orleans (November 1976)
Trappe, B.: Doxepin and amitriptyline-chlordiazepoxide combination in neurotic states. A comparative double-blind trial. Current Medical Research and Opinion 2 (Suppl): 71 (1975)
Tuomisto, J.: A new modification for studying 5-HT uptake by blood platelets: A re-evaluation of tricyclic antidepressants as uptake inhibitors. Journal of Pharmacy and Pharmacology 26: 92(1974)
Van Praag, H.M.: Screening and evaluation of antidepressives. Geneesk Gids 2: 51 (1969)
Van Riezen, H. and Delver, A.: The effect of a number of drugs with different pharmacological properties upon reserpine-induced hypothermia in mice. Arzneimittel-Forschung 21: 1562 (1971)
Vitorovic, M. and Zvan, V.: Our first experience with the new antidepressive medicament doxepin (Sinequan-Pfizer). Medical Journal of Slovenia (Yugoslavia) 39: 129 (1970)
Vohra, J.; Burrows, G.; Hunt, D. and Sloman, G.: The effect of toxic and therapeutic doses of tricyclic antidepressant drugs on intracardiac conduction. European Journal of Cardiology 3: 219 (1975b)
Vohra, J.; Burrows, G.D. and Sloman, G.: Assessment of cardiovascular side-effects of therapeutic doses of tricyclic antidepressant drugs. Australia and New Zealand Journal of Medicine 5: 7 (1975a)
Vohra, J.; Hunt, D.; Burrows, G.D. and Sloman, G.: Intracardiac conduction defects following overdose of tricyclic antidepressant drugs. European Journal of Cardiology 2/ 4: 453 (1975c)
Wiener, K.: Ergebnisse einer klinischen Pruefung von Doxepin bei Asthma bronchiale. Medizinische Welt 22: 1343 (1971)
Williams, J.O.: Respiratory depression in tricyclic overdosage. British Medical Journal 1: 631 (1972)
Wohlfarth-Ribbentrop, A. and Schaumann, W.: Tierexperimentelle Vergleich der tranquili siereiden Wirkung von Doxepin mit bekamten Psychopharmaka. Arzneimittel-Forschung 19: 2012(1969)
Woody, G.E.; O’Brien, C.P. and Rickeis, K.: Depression and anxiety in heroin addicts: A placebo-controlled study of doxepin in combination with methadone. American Journal of Psychiatry 132: 447(1975)
Zielinski, M.; Janiec, W. and Herman, Z.S.: Central action of 11-(3-dimethyl-aminopropylidene)-6,11-dihydrodibenzo [b,e]oxepine hydrochloride (Doxepin). Polish Journal of Pharmacology and Pharmacy 25: 17 (1973)
Author information
Authors and Affiliations
Additional information
Various sections of the manuscript reviewed by: F.J. Ayd, Baltimore, Md. USA; T.A. Ban, Tennessee Neuropsychiatric Institute, Nashville, Tenn. USA; G. Bianchi, Bardon West, Australia; K.H. Boysen, Vienna, Austria; G.D. Burrows, Department of Psychiatry, University of Melbourne, Australia; B. Davies, Department of Psychiatry, University of Melbourne, Australia; J.M. Davis, Illinois State Psychiatric Institute, Chicago, III. USA; E. Ebnen, Department of Pharmacology, University of Helsinki, Finland; W.E. Fann, Department of Psychiatry, Baylor College of Medicine, Houston, Texas, USA; R.O. Friedel, Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, Wash. USA; H.L. Goldberg, West-Ros-Park Mental Health Center, Hyde Park, Mass. USA; B.J. Goldstein, Departments of Psychiatry and Pharmacology, University of Miami, Florida, USA; L.H. Hollister, Veterans Administration Hospital, Palo Alto, Calif. USA; J.W. Jefferson, Department of Psychiatry, University of Wisconsin-Madison, USA; I. Karacan, Department of Psychiatry, Sleep Disorders Center, Baylor College of Medicine, Houston, Texas, USA; A. Kiev, Cornell University Medical College, New York, NY, USA; M. Kimura, Psychotherapeutic Internal Department, Kyushu University, Fukuoka, Japan; N.S. Kline, Department of Mental Hygiene, Rockland Research Institute, Orangeburg, New York, USA; A.J. Krakowski, Plttsburgh, NY, USA; M. Lader, Institute of Psychiatry, De Crespigny Park, London, England; M. Manila, Department of Pharmacology, University of Helsinki, Finland; E. Radmayr, Facharzt fur Neurologie und Psychiatrie, Dornbirn, West Germany; K. Rickels, Department of Psychiatry, University of Pennsylvania, Philadelphia, Pa. USA; M. Toru, Department of Neuropsychiatry, Tokyo Medical and Dental School, Japan; J.K. Vohra, Cardiac Department, Royal Melbourne Hospital, Australia.
‘Sinequan’, ‘Sinquan’ (Pfizer); ‘Adapin’ (Pennwalt); ‘Aponal’, ‘Curatin’, ‘Quitaxon’ (Boehringer Mannheim)
Rights and permissions
About this article
Cite this article
Finder, R.M., Brogden, R.N., Speight, T.M. et al. Doxepin Up-to-Date: A Review of its Pharmacological Properties and Therapeutic Efficacy with Particular Reference to Depression. Drugs 13, 161–218 (1977). https://doi.org/10.2165/00003495-197713030-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-197713030-00001